Cargando…

An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer

PURPOSE: Gold-marker-based image-guided radiation therapy (IGRT) of the prostate allows to correct for inter- and intrafraction motion and therefore to safely reduce margins for the prostate planning target volume (PTV). However, pelvic PTVs, when coadministered in a single plan (registered to gold...

Descripción completa

Detalles Bibliográficos
Autores principales: Groher, M., Kopp, P., Drerup, M., Deutschmann, H., Sedlmayer, F., Wolf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570790/
https://www.ncbi.nlm.nih.gov/pubmed/28726055
http://dx.doi.org/10.1007/s00066-017-1182-1
_version_ 1783259219162562560
author Groher, M.
Kopp, P.
Drerup, M.
Deutschmann, H.
Sedlmayer, F.
Wolf, Frank
author_facet Groher, M.
Kopp, P.
Drerup, M.
Deutschmann, H.
Sedlmayer, F.
Wolf, Frank
author_sort Groher, M.
collection PubMed
description PURPOSE: Gold-marker-based image-guided radiation therapy (IGRT) of the prostate allows to correct for inter- and intrafraction motion and therefore to safely reduce margins for the prostate planning target volume (PTV). However, pelvic PTVs, when coadministered in a single plan (registered to gold markers [GM]), require reassessment of the margin concept since prostate movement is independent from the pelvic bony anatomy to which the lymphatics are usually referenced to. METHODS: We have therefore revisited prostate translational movement relative to the bony anatomy to obtain adequate margins for the pelvic PTVs compensating mismatch resulting from referencing pelvic target volumes to GMs in the prostate. Prostate movement was analyzed in a set of 28 patients (25 fractions each, totaling in 684 fractions) and the required margins calculated for the pelvic PTVs according to Van Herk’s margin formula [Formula: see text] . RESULTS: The overall mean prostate movement relative to bony anatomy was 0.9 ± 3.1, 0.6 ± 3.4, and 0.0 ± 0.7 mm in anterior/posterior (A/P), inferior/superior (I/S) and left/right (L/R) direction, respectively. Calculated margins to compensate for the resulting mismatch to bony anatomy were 9/9/2 mm in A/P, I/S, and L/R direction and 10/11/6 mm if an additional residual error of 2 mm was assumed. CONCLUSION: GM-based IGRT for pelvic PTVs is feasible if margins are adapted accordingly. Margins could be reduced further if systematic errors which are introduced during the planning CT were eliminated.
format Online
Article
Text
id pubmed-5570790
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55707902017-09-19 An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer Groher, M. Kopp, P. Drerup, M. Deutschmann, H. Sedlmayer, F. Wolf, Frank Strahlenther Onkol Short Communication PURPOSE: Gold-marker-based image-guided radiation therapy (IGRT) of the prostate allows to correct for inter- and intrafraction motion and therefore to safely reduce margins for the prostate planning target volume (PTV). However, pelvic PTVs, when coadministered in a single plan (registered to gold markers [GM]), require reassessment of the margin concept since prostate movement is independent from the pelvic bony anatomy to which the lymphatics are usually referenced to. METHODS: We have therefore revisited prostate translational movement relative to the bony anatomy to obtain adequate margins for the pelvic PTVs compensating mismatch resulting from referencing pelvic target volumes to GMs in the prostate. Prostate movement was analyzed in a set of 28 patients (25 fractions each, totaling in 684 fractions) and the required margins calculated for the pelvic PTVs according to Van Herk’s margin formula [Formula: see text] . RESULTS: The overall mean prostate movement relative to bony anatomy was 0.9 ± 3.1, 0.6 ± 3.4, and 0.0 ± 0.7 mm in anterior/posterior (A/P), inferior/superior (I/S) and left/right (L/R) direction, respectively. Calculated margins to compensate for the resulting mismatch to bony anatomy were 9/9/2 mm in A/P, I/S, and L/R direction and 10/11/6 mm if an additional residual error of 2 mm was assumed. CONCLUSION: GM-based IGRT for pelvic PTVs is feasible if margins are adapted accordingly. Margins could be reduced further if systematic errors which are introduced during the planning CT were eliminated. Springer Berlin Heidelberg 2017-07-19 2017 /pmc/articles/PMC5570790/ /pubmed/28726055 http://dx.doi.org/10.1007/s00066-017-1182-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Communication
Groher, M.
Kopp, P.
Drerup, M.
Deutschmann, H.
Sedlmayer, F.
Wolf, Frank
An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
title An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
title_full An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
title_fullStr An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
title_full_unstemmed An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
title_short An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer
title_sort igrt margin concept for pelvic lymph nodes in high-risk prostate cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570790/
https://www.ncbi.nlm.nih.gov/pubmed/28726055
http://dx.doi.org/10.1007/s00066-017-1182-1
work_keys_str_mv AT groherm anigrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT koppp anigrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT drerupm anigrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT deutschmannh anigrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT sedlmayerf anigrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT wolffrank anigrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT groherm igrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT koppp igrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT drerupm igrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT deutschmannh igrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT sedlmayerf igrtmarginconceptforpelviclymphnodesinhighriskprostatecancer
AT wolffrank igrtmarginconceptforpelviclymphnodesinhighriskprostatecancer